Protalix BioTherapeutics Inc (PLX)
1.18
-0.03
(-2.48%)
USD |
NYAM |
Apr 25, 16:00
1.20
+0.02
(+1.69%)
Pre-Market: 20:00
Protalix BioTherapeutics Gross Profit Margin (Quarterly): 15.54% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.54% |
| September 30, 2023 | 52.70% |
| June 30, 2023 | 82.47% |
| March 31, 2023 | 67.82% |
| December 31, 2022 | 72.18% |
| September 30, 2022 | 50.12% |
| June 30, 2022 | 53.31% |
| March 31, 2022 | 62.49% |
| December 31, 2021 | 63.18% |
| September 30, 2021 | 69.28% |
| June 30, 2021 | 26.36% |
| March 31, 2021 | 57.91% |
| December 31, 2020 | 85.88% |
| September 30, 2020 | 73.42% |
| June 30, 2020 | 83.34% |
| March 31, 2020 | 84.17% |
| December 31, 2019 | 83.39% |
| September 30, 2019 | 77.51% |
| June 30, 2019 | 77.99% |
| March 31, 2019 | 80.41% |
| December 31, 2018 | 78.00% |
| September 30, 2018 | 84.46% |
| June 30, 2018 | 54.88% |
| March 31, 2018 | 56.45% |
| December 31, 2017 | 63.90% |
| Date | Value |
|---|---|
| September 30, 2017 | 19.40% |
| June 30, 2017 | 13.13% |
| March 31, 2017 | 27.73% |
| December 31, 2016 | 6.20% |
| September 30, 2016 | 9.04% |
| June 30, 2016 | 5.31% |
| March 31, 2016 | 22.98% |
| December 31, 2015 | |
| September 30, 2015 | 83.31% |
| June 30, 2015 | 83.16% |
| March 31, 2015 | 83.33% |
| December 31, 2014 | 33.23% |
| September 30, 2014 | 51.50% |
| June 30, 2014 | 40.25% |
| March 31, 2014 | 44.83% |
| December 31, 2013 | 62.70% |
| September 30, 2013 | 52.75% |
| June 30, 2013 | 56.98% |
| March 31, 2013 | 75.53% |
| December 31, 2012 | -2.35K% |
| September 30, 2012 | 56.09% |
| June 30, 2012 | 87.02% |
| March 31, 2012 | 64.59% |
| December 31, 2011 | 42.67% |
| September 30, 2011 | 75.47% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
15.54%
Minimum
Dec 2023
85.88%
Maximum
Dec 2020
65.21%
Average
69.28%
Median
Sep 2021
Gross Profit Margin (Quarterly) Benchmarks
| Agenus Inc | 20.07% |
| InfuSystems Holdings Inc | 46.84% |
| Corbus Pharmaceuticals Holdings Inc | -- |
| AIM ImmunoTech Inc | 81.54% |
| Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 41.07% |
| Return on Assets | 10.86% |
| Return on Invested Capital | 19.05% |
| Profit Margin (Quarterly) | -57.64% |
| Operating Margin (Quarterly) | -53.55% |
| Return on Net Operating Assets | 23.86% |